ocular drug delivery Flashcards

1
Q

what are the different layers of the eyes

A

outer - sclera and cornea
middle- iris, ciliary body and choroid
inner - retina
chambers - anterior and posterior, vitreous cavity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are the barriers to topical ocular ddel

A

pre-corneal factors
- solution drainage, blinking, tear film, tear turnover
- induced lacrimation
- mucin in tear film is hydrophobic
anatomical
- layers of cornea, conjunctiva and sclera

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are the barriers to systemic ocular ddel

A

blood aqueous barrier
blood retinal barrier

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

why is the blood retinal barrier a barrier to systemic ocular ddel

A

requires specific targeting systems, limited access requires high oral doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what considerations need to be made when developing drugs for ocular delivery

A

osmolarity
pH
surface tension
viscosity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

why does osmolarity need to be considered when developing drugs for ocular delivery

A

determined by concentration of lacrimal fluids - 0.9-1%
hypotonic cause oedema, hypertonic dry the corneal epithelium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

why does pH need to be considered when developing drugs for ocular delivery

A

important in controlling ionisation and corneal permeability (6.9-7.5)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

why does surface tension need to be considered when developing drugs for ocular delivery

A

drops that lower the surface tension of the eye
- destabilise tear film
- disperse lipids into droplets
- solubilised by drug/surfactants in formulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

why does viscosity need to be considered when developing drugs for ocular delivery

A

to prolong retention in tear film
PVP, PVA, MC, HPMC
blinking force limits viscosity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are the advantages and disadvantages of using solutions for topical ocular ddel

A

easy and cheap
rapid onset of action with good dose uniformity
rapidly drained from the eye - proportional to drop size
variations in amount dispensed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

why are suspensions used for ocular ddel

A

administration of soluble aqueous drugs - steroids and to prolong release

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

why are gels used in ocular ddel

A

semi-solid with water soluble base - polymers dispersed in liquids
can be activated to undergo phase transition in the eye

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what are the 3 routes of systemic/direct ocular ddel

A

intracameral - anterior chambers
intravitreal
periocular (subconjunctival, retrobulbar and peribulbar)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are the advantages and disadvantages of intravitreal injection for ocular ddel

A

 Distribution in vitreous is non-uniform – LMW can rapidly distribute, HMW cannot
 Best way to deliver but poor compliance
 Drug retention requires frequent administration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are punctual plugs

A

plugs inserted into tear ducts that release drugs over 1-2m

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are the two types of implant for ocular ddel

A
  • Fluocinolone over 3 yrs – non-bioerodible
  • Latanoprost, subconjunctival space, 3m as is bioerodible
17
Q

what is iontophoresis and how is it used in ocular ddel

A
  • The basic electrical principle that oppositely charged ions attract and same charged ions repel is the central tenet of iontophoresis.
  • The ionized substances are driven into the tissue by electrorepulsion at either the anode (for positive drug) or the cathode (for negatively charged drug)
  • ocular iontophoresis is capable of delivering substantially higher ocular drug concentrations than traditional topical applications, leading to greater bioavailability and more sustained therapeutic effect and reducing the frequency of dosing
18
Q

what are drug eluting contact lenses

A

drug coated on or imprinted on inner side of lenses – provides steady drug release

19
Q

what are topical ophthalmic drug delivery devices

A
  • device floats on the sclera under eyelid
  • 3-90 days of delivery
  • Human clinical trials
20
Q

what is triggerfish

A
  • Contact lens providing constant IOP readings
  • Sensor contains strain gauges that measure corneal curvature changes caused by intraocular pressure variations